OTC Markets Are the Whipping Post for Too Many Microcap Stocks

Image: Cover of debut album by The Allman Brothers Band. Atco Records, Capricorn Records, 1969

Sometimes I feel, sometimes I feel,

Like I been tied to the whippin’ post.

Tied to the whippin’ post, tied to the whippin’ post.

Good Lord, I feel like I’m dyin’.

– Whipping Post, The Allman Brothers Band, 1969*

This is a reprint of an article of mine originally published by equities.com here.

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++

Previous articles of mine have described the disappearing US publicly traded company, the inhospitability of the US public markets to smaller cap companies, and the disappearing smaller IPO.[1]

After reading these and similar articles one might reasonably conclude that the US exchange-listed markets are dying.[2] This is a fair characterization, based on the objective measures of there being 40% fewer publicly-listed companies than there were 20 years and ago and approximately 4,500 fewer publicly-listed companies than the US should have based on GDP comparison with other countries.

Thankfully, under the leadership of SEC Chairman Jay Clayton, the SEC is now focused on the dying US publicly listed markets and is examining potential regulatory initiatives to reverse this trend.[3] I am particularly encouraged by the SEC’s proposed changes to the Reg. A and Crowdfunding rules that it promulgated this week. Those changes would greatly improve prospects for private capital formation.

This article examines the state of the other component of the US public markets, the publicly-traded OTC Markets.[4]

Capital markets policy makers and regulators over the last decade or more have been singularly focused on investor protection, trading efficiencies, and anti-money laundering. Of course, that is not a bad thing, since these are laudatory objectives. The unintended consequence of this singular focus, though, is that little-to-no attention has been given to policies that promote entrepreneurship, private capital formation, and access to capital for startups, which are the lifeblood of the US economy.

The consequent dying of the exchange-listed markets is bad enough: let’s now consider the plight of the OTC Markets, which are in a far worse circumstance than either the NYSE or Nasdaq markets, as illuminated by the following data points.

Data point #1.

Of the top 20 OTC Markets traded issuers by volume, exactly 0 of them are US companies. Yes, you read that correctly. Of the top 20 OTC Markets traded issuers,[5] comprising 83% of daily trading volume,[6] ZERO, ZIP, NADA, NONE of them is actually a US company.7

Data point #2.

As of a recent date, 90% of the OTC market making was performed by only eight market makers.[8] Moreover, only 43 market makers traded at least one share on the OTC Markets marketplace. This represents a 89% decrease from the over 400 OTC market makers in 1997.[9]

Data point #3

Since as noted above 20 OTC Markets traded companies account for 83% of the daily trading volume,[10] the remaining 10,797 OTC Markets traded companies account for just 17% of the trading volume. Common sense informs us that the preponderance of these remaining issuers have illiquid stocks. And, indeed that is the case particularly for the nano-cap issuers with less than $50 million in market cap. The average daily dollar volume for the 393 companies in the OTCQB tier was only approximately $31,000 according to 2018 data. Some of these companies have daily trading volumes amounting to merely hundreds of dollars per share per day.

Data point #4.

Zealous enforcement of the anti-money laundering (AML) rules by the SEC and FINRA discourages firms from making a market in OTC Markets issuers. The number of AML cases brought by the regulators against nearly all customer servicing firms and the fine amounts against those firms is astonishing. US regulators imposed a total of $19.85 billion in AML fines between 2002 and April 2019.[11]

I am told by colleagues who have dealt with the regulators that nearly all firms settle these regulatory actions rather than contest them. It is virtually impossible to successfully defend them because the enforcement actions typically involve hypothetical “could/should have” allegations, rather than an actual money laundering transaction. Further, the courts typically give deference to the regulator’s interpretation of the regulations.

These regulatory actions typically involve a metaphysical evaluation by the regulator, in the regulator’s subjective view, of whether or not a firm’s policies or procedures are “strong enough” to stop or prohibit money laundering, or whether or not the firm “could have” done more to detect hypothetical money laundering, or whether or not the firm “should have” more robust policies or procedures to detect hypothetical money laundering. Keep in mind that rarely is money laundering proven or even alleged by the regulator.

In such case when there is no incident that has actually occurred, it is virtually impossible to defend against a regulator’s subjective view that more “could/should” have been done by the firm. It is no wonder that nearly all firms settle these regulatory actions, rather than contest them.

Many regulatory sanctions against firms relate to “suspicious activity reports” (SARs). The regulators can fine a firm if the regulator determines:

  • that the firm should have filed a SAR – even though the firm determined in the exercise of its good faith business judgment that the activity didn’t rise to a level requiring the filing of a SAR; or
  • that the firm did not provide enough detail – even though the firm provided the facts and circumstances; or
  • that the firm did not file the SAR quickly enough [12] — even though the firm did in fact file the SAR; or
  • that the firm filed too many SARs. [13]

Of course, the regulators have the benefit of hindsight and typically are judging the firm against a hypothetical, subjective standard as opposed to an actual incident of untoward activity. The regulator initiates an action and typically prevails by merely alleging that the firm did not file the SAR in a timely enough fashion, the filed SAR lacked sufficient detail, the firm should have filed a SAR, the firm filed too many SARs, etc. In other words, whatever the firm did or didn’t do, it should have done it better.

This overreaching by the regulators acutely manifests in the OTC Markets and in the lower-priced NASDAQ issuer ecosphere because customary behavior and activity in this ecosphere are “red-flags” that could/should have trigger(ed) a SAR filing in the eyes of the regulator. See the following examples of ordinary and customary behavior in the smaller cap, thinly-traded issuer ecosphere that are FINRA “red flags”[14] requiring the filing of a SAR.

  • A customer opens a new account and deposits physical certificates, or delivers in shares electronically, representing a large block of thinly traded or low-priced securities.

Comment: “Large block” is not defined – I have been told that regulators consider 10,000 shares or more a large block. For smaller cap issuers, with thinly traded and lower priced securities, virtually every stockholder owns more than 10,000 shares requiring deposit. 10,000 shares of a $.50 stock = $5,000. Nothing out of the ordinary here in the smaller cap ecosphere, but it is a “suspicious activity” for SAR purposes.

  • A customer has a pattern of depositing physical share certificates, or a pattern of delivering in shares electronically, immediately selling the shares and then wiring, or otherwise transferring out the proceeds of the sale(s).

Comment: This is common practice in the smaller cap issuer, thinly traded ecosphere. A stockholder, who has held paper certificates for months, if not years, wants to sell the shares, so the stockholder opens an account at one of the few brokerage firms that actually will accept the paper certificates and process a sale transaction. The stockholder then wires the money to the stockholder’s normal brokerage account. Nothing out of the ordinary here in the smaller cap ecosphere, but it is a “suspicious activity” for SAR purposes.

  • Seemingly unrelated clients open accounts on or at about the same time, deposit the same low-priced security and subsequently liquidate the security in a manner that suggests coordination.

Comment: Since very few firms accept deposits in low priced securities, it is very common to have one firm receive multiple shareholder deposits in an issuer’s securities at or around the same time. Nothing out of the ordinary here in the smaller cap ecosphere, but it is a “suspicious activity” for SAR purposes.

  • There is a sudden spike in investor demand for, coupled with a rising price in, a thinly traded or low-priced security.

Comment: Price movements are always exaggerated in thinly traded securities. Nothing out of the ordinary here in the smaller cap ecosphere, but it is a “suspicious activity” for SAR purposes.

  • The customer’s activity represents a significant proportion of the daily trading volume in a thinly traded or low-priced security.

Comment: Individual sales in a thinly-traded security typically represent a significant portion of the daily trading volume. For example, a customer sells 1,000 shares of a $.50 stock in a security that trades 2,000 shares daily on average represents majority of the trading volume. Nothing out of the ordinary here in the smaller cap ecosphere, but it is a “suspicious activity” for SAR purposes.

  • The customer is known to have friends or family who work at or for the securities issuer, which may be a red flag for potential insider trading or unlawful sales of unregistered securities.

Comment: Guess what? Private securities offerings of smaller cap issuers ALWAYS involve selling shares to friends and family. Nothing out of the ordinary here in the smaller cap ecosphere, but it is a “suspicious activity” for SAR purposes.

Not surprisingly, many firms have simply stopped allowing deposits, resales and sometimes even purchases of low-priced securities. This reminds me of a classic Ronald Reagan quote regarding a regulator’s view of economic activity: “If it moves, tax it. If it keeps moving, regulate it. And if it stops moving, subsidize it.”

As stated in an earlier article, I am aware of only one firm that accepts deposits of paper certificates. If readers know of firms that do accept deposits of paper certificates, please let me know and I will compile and publish a list.

The regulators have almost succeeded in killing the ability of OTC-traded issuers to raise capital in private offerings. If investors are unable to deposit the paper certificates and sell the shares, they will cease investing in OTC-traded issuers, which are already starving for capital.

[Notes appear below]

* A reader suggested this would be an apropos title for an article discussing the OTC Markets since most OTC Markets companies are tied to the “whipping post” of low trading liquidity, virtually no investment analyst coverage, and virtually no non-toxic capital, which collectively create an inhospitable environment.

1. The decline in the number of US publicly listed companies (so-called “listing gap”) is virtually 100% explained by the disappearance of the smaller IPO (<$50 – $100 million) beginning in 2000, i.e., smaller-cap companies began avoiding the public markets in droves since 1999. See “Hunting High & Low: The Decline of the Small IPO and What to Do About It.” Lux and Pead, April 2018 at p. 8.

2. “Exchange-listed” refers to issuers listed on Nasdaq and NYSE.

3. One recent example is the SEC’s request for suggestions to alleviate the plight of thinly-traded issuers. See the Commission Statement on Market Structure Innovation for Thinly Traded Securities.

4. Special thanks to Mr. David Lopez, CEO of Matador Capital Markets, and former broker-dealer compliance officer, for providing much of the data included in this article.

5. There were 10,817 OTC issuers as of a recent date.

6. These 20 symbols accounted for 83% of the total $874,977,308 OTC Market daily trading volume as of a recent date, according to OTC Markets.

7. Three of them are domiciled in the US (Greyscale Bitcoin Trust, Freddie Mac and Fannie Mae), but none of those are corporate operating businesses. The remaining 17 are foreign common stock or American Depositary Receipts (ADR) issuers.

8. These market makers accounted for $273,637,588 of the total $304,332,336 OTC market maker daily trading volume as of a recent date, according to OTC Markets.

9. See SEC Release No. 34-39670; File No. 57-3-98, February 17, 1998.

10. See footnote 6 above

11. Data from Comply Advantage.

12. The regulator is judging from its “ivory tower” perspective of how quickly the busy brokerage firm, which is monitoring the activities of dozens or hundreds of brokers, processing daily tens of thousands of stock transactions, and opening and closing dozens of accounts daily, should have filed the form.

13. A firm is fined if it files too few SARs and if it files too many SARs.

14. There are 98 FINRA red flags that require a SAR filing.

OTC Stocks and the ‘Hotel California’ Problem

This is a reprint of my article originally published by equities.com here.

Many smaller cap stocks are illiquid compared to their larger cap cousins. 40% of the ticker symbols traded on NASDAQ and NYSE have average daily trading (ADV) volumes of less than 50,000 shares per day, according to the SEC. The median ADV within this group is only 10,000 shares per day. 50% of these ticker symbols have ADV of less than 100,000 shares a day.

Adam Epstein, nationally recognized small-cap expert and author of the “Systemically Overlooked Anomalies of Governing Small-Cap Companies” chapter of the Handbook of Board Governance: A Comprehensive Guide for Public, Private and Not for Profit Board Members (Wiley, 2016), has said that investing in smaller-cap NMS companies with illiquid stock presents the “Hotel California” problem for investors: they can invest in the company, but because of the stock trading liquidity, it’s virtually impossible to exit their stock position: “You can you check out any time you like, but you can never leave.”1

The ability of smaller cap stocks with low trading volumes to attract non-toxic professional investment capital approaches ZERO for reasons illuminated in earlier articles of mine.

Stocks traded on OTC Markets—about three times the total number of companies listed on the NYSE and Nasdaq combined—have two Hotel California problems. The first is that for most OTC Markets traded issuers, their stocks are LESS liquid than NYSE/Nasdaq stocks. The daily trading volumes for many OTC Markets traded companies is in the HUNDREDS of shares a day, i.e., virtually ZERO trading volume. Increasing their companies’ stock trading liquidity was the#1 capital markets priority for 80% of the CEOs/CFOs of OTC Markets issuers in a 2017 survey.2

The second Hotel California problem presents itself in this circumstance: to sell one’s OTC stock (other than in a privately negotiated sale), it is necessary to deposit the paper certificates with a brokerage firm. It is very, very difficult to find a brokerage firm to take possession of paper stock certificates.

Consider this scenario. An OTC Markets issuer raises needed capital in a private placement and sells shares of stock at, say, $.50 per share. The investor receives a paper stock certificate for the shares it has acquired. The company’s business progresses over the next 12 months and its stock price increases to $2.00 per share on reasonable trading volumes. With the Rule 144 holding period having elapsed, the investor decides to sell the shares for what should be a nice 300% gain. The investor call its brokerage firm to sell the shares. Guess what?

The brokerage firm refuses to take custody of the shares, citing the firm’s compliance department as the reason. The investor calls a dozen other brokerage firms and cannot find any that is willing to take the shares.3 The investor is unable to sell its shares to monetize its gain.

This is a very, very serious problem for OTC Markets traded companies. In fact, if investors in OTC Markets traded companies actually knew how difficult it would be to sell their shares, it’s reasonable to think that many of them would not have invested in the first instance.

All is not lost. As noted in my earlier articles on Equities.com, there are lawful and effective strategies for increasing stock trading liquidity. Contact me through LinkedIn at linkedin.com/in/ronwoessner for more information on this topic.

_____

Lyrics to “Hotel California” by the Eagles.

2 Reported in the 2017 OTC Markets CEO/CFOs survey. The #2 priority was increasing the company share price, and the #3 priority was raising capital.

3 I’ve been told there is at least one brokerage firm that will take possession of OTC Markets traded shares, and I’m told the sales transaction fees are very expensive.

Going Public is an “On Ramp to Nowhere”​ for Smaller Cap Issuers

There has been much commentary about expanding the public company “on ramp” by making it easier for companies to go public. JOBS Act 2.0 made meaningful progress in that regard. Unfortunately, the U.S. public markets are an “on-ramp to nowhere” for many smaller-cap issuers because the public markets are inhospitable to smaller cap companies. Manifestations of this inhospitability are illuminated in a LinkedIn article appearing here, articles published by equities.com appearing here, and in my Response to Commission Statement on Market Structure Innovation for Thinly Traded Securities [Release No. 34-87327; File No. S7-18-19] published just TODAY by the SEC.

Quoting from slides 2 and 3 of the SEC filing:

  • As long as the view from the IPO “on-ramp” suggests that the prospects of taking on all the additional costs and risks of going public, but struggling to capitalize the benefits, many start-up founders, managers and investors will continue to think twice about choosing to finance their growth via the public market.
  • There are thousands of smaller-cap public companies, including OTC Markets issuers, that have the potential to create millions of jobs and grow GDP.
  • Many of these companies are “dying on the vine” because of their inability to access non-toxic capital and other inhospitable attributes of the US public markets.
  • Thousands of these issuers with the potential to grow, thrive and become vibrant NYSE or NASDAQ issuers and veritable job and GDP creation machines, NEVER will achieve that. Many will stagnate; others will go out of business … with the foreseeable result that the number of US publicly listed issuers will continue to decline, and one day there will be insufficient large cap issuers for Fidelity, Vanguard, large pension funds, etc. to invest in.

Read the entire filing at https://www.sec.gov/comments/s7-18-19/s71819-6671698-204008.pdf.

Thank you for your interest as we continue the struggle to keep the US public markets the world’s pre-eminent capital market and prevent the Chinese from overtaking America.